Introduction:Neisseria gonorrhoeae is a notorious superbug responsible for causing
‘Gonorrhoea’ in humans. Recently, it has been classified as a high-priority pathogen by the World
Health Organization due to its increasing resistance to available antibiotics. A multi-prolonged
approach is needed to combat the growing problem of drug resistance caused by N. gonorrhoeae.
This study evaluates Glutamate Racemase (GR), a moonlighting protein of N. gonorrhoeae (Ng-
GR), as a novel therapeutic target with potential for both inhibitor design and peptide vaccine development.
Ng-GR plays a crucial role in the peptidoglycan biosynthetic pathway and is highly
conserved across bacterial species. Additionally, this protein moonlights to perform a secondary
function by binding to DNA gyrase in various organisms.Method:Homology modeling, molecular docking, and molecular dynamics simulations were used
to design inhibitors targeting the moonlight function of Ng-GR. The immunogenicity of this protein
was assessed using ABCPred-2.0, BepiPred-2.0, and ProPred software.Results:Bisleucocurine A was found to bind at the ectopic site of Ng-GR, disrupting its crucial
moonlight function and interfering with the interaction between Ng-GR and N. gonorroheae DNA
Gyrase (Ng-gyrase). Interestingly, residues important for its moonlight function were also identified
as key immunogenic sites using ABCPred-2.0, BepiPred-2.0, and ProPred software, enhancing
the potential of this protein as a vaccine candidate.Conclusion:The GR enzyme’s moonlight function is highlighted as a promising novel target for
therapeutic intervention and vaccine development in N. gonorrohoeae.